Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2011-04-19
2011-04-19
Mosher, Mary E (Department: 1648)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C435S005000, C435S029000, C436S501000, C436S518000
Reexamination Certificate
active
07927580
ABSTRACT:
A method for identifying new immunomodulatory chemical entities (NICE) comprising reacting a candidate NICE with a Tat SH3 binding domain, identifying the bound candidate NICE and determining whether the candidate NICE induces monocytes to differentiate into dendritic cells (DC) or regulatory macrophages (AReg). In particular, the present invention relates to identifying NICE that are either immunostimulatory or immunosuppressive.
REFERENCES:
patent: 5585103 (1996-12-01), Raychaundhuri et al.
patent: 5597895 (1997-01-01), Gaynor et al.
patent: 5616559 (1997-04-01), Androphy et al.
patent: 5652122 (1997-07-01), Frankel et al.
patent: 5656599 (1997-08-01), Androphy et al.
patent: 5670617 (1997-09-01), Frankel et al.
patent: 5674980 (1997-10-01), Frankel et al.
patent: 5686264 (1997-11-01), Gaynor et al.
patent: 5747641 (1998-05-01), Frankel et al.
patent: 5804604 (1998-09-01), Frankel et al.
patent: 5889175 (1999-03-01), Mehtali et al.
patent: 5891994 (1999-04-01), Goldstein
patent: 5942401 (1999-08-01), van Baalen et al.
patent: 5981258 (1999-11-01), Mehtali et al.
patent: 6024965 (2000-02-01), van Baalen et al.
patent: 6132721 (2000-10-01), Zagury et al.
patent: 6193981 (2001-02-01), Goldstein
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6200575 (2001-03-01), Zagury et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6228369 (2001-05-01), Mehtali et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6270769 (2001-08-01), Raychaudhuri et al.
patent: 6284252 (2001-09-01), Mehtali et al.
patent: 6316003 (2001-11-01), Frankel et al.
patent: 6319666 (2001-11-01), van Baalen et al.
patent: 6339068 (2002-01-01), Krieg et al.
patent: 6406705 (2002-06-01), Davis et al.
patent: 6420141 (2002-07-01), Zagury et al.
patent: 6495347 (2002-12-01), Siegel et al.
patent: 6497880 (2002-12-01), Wisniewski
patent: 6524582 (2003-02-01), Goldstein
patent: 6524825 (2003-02-01), Mizzen et al.
patent: 6525179 (2003-02-01), Goldstein
patent: 6593292 (2003-07-01), Rothbard et al.
patent: 6657055 (2003-12-01), Siegel et al.
patent: 6667151 (2003-12-01), Cohen
patent: 6686333 (2004-02-01), Kashanchi et al.
patent: 6797491 (2004-09-01), Neefe et al.
patent: 2002/0091073 (2002-07-01), Finkel et al.
patent: 2002/0193330 (2002-12-01), Hone
patent: 2002/0197269 (2002-12-01), Lingnau et al.
patent: 2003/0003106 (2003-01-01), Zagury et al.
patent: 2003/0091599 (2003-05-01), Davis et al.
patent: 2003/0099663 (2003-05-01), Fleitmann et al.
patent: 2003/0099664 (2003-05-01), Wisniewski
patent: 2003/0148456 (2003-08-01), Mizzen et al.
patent: 2003/0158134 (2003-08-01), Voss
patent: 2003/0162719 (2003-08-01), Rothbard et al.
patent: 2003/0166832 (2003-09-01), Goldstein
patent: 2003/0180326 (2003-09-01), Goldstein
patent: 2003/0224010 (2003-12-01), Davis et al.
patent: 2003/0232074 (2003-12-01), Lipford et al.
patent: 2004/0001852 (2004-01-01), Zagury et al.
patent: 2004/0005330 (2004-01-01), Rappaport et al.
patent: 2004/0009949 (2004-01-01), Krieg
patent: 2004/0028652 (2004-02-01), Wang et al.
patent: 2004/0034209 (2004-02-01), Ho et al.
patent: 2004/0054137 (2004-03-01), Thomson et al.
patent: 0 673 948 (1998-11-01), None
patent: 0 814 834 (2000-09-01), None
patent: 1 279 404 (2003-01-01), None
patent: 91/15224 (1991-10-01), None
patent: 91/18454 (1991-11-01), None
patent: 94/15634 (1994-07-01), None
patent: 95/31999 (1995-11-01), None
patent: 96/27389 (1996-09-01), None
patent: 98/14589 (1998-04-01), None
patent: 98/17309 (1998-04-01), None
patent: 98/43669 (1998-10-01), None
patent: 98/46083 (1998-10-01), None
patent: 99/02185 (1999-01-01), None
patent: 99/16884 (1999-04-01), None
patent: 99/27958 (1999-06-01), None
patent: 99/33346 (1999-07-01), None
patent: 99/33872 (1999-07-01), None
patent: 00/03732 (2000-01-01), None
patent: 00/78334 (2000-12-01), None
patent: 00/78969 (2000-12-01), None
patent: 01/00232 (2001-01-01), None
patent: 01/24822 (2001-04-01), None
patent: 01/43771 (2001-06-01), None
patent: 01/78775 (2001-10-01), None
Darbinian, et al. Functional interaction between cyclin T1rcdk9 and Pura determines the level of TNFa promoter activation by Tat in glial cells. Journal of Neuroimmunology 121{hacek over (Z)}2001.3-11.
Cohen, et al. “Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge” Proceedings of the National Academy of Sciences of the United States of America. 1999; 96(19):10842-10847.
Cheadle, et al. “Identification of a Src SH3 domain binding motif by screening a random phage display library” Journal of Biological Chemistry. 1994; 269(39):24034-24039.
Bagh Ian, et al. “Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based im munisation with herpes simplex virus type-I genes specifying glycoproteins gB and gD” Journal of Medical Microbiology. 2002; 51(4): 350-357.
Agwale SM et al. A Tat subunit vaccine confers protective immunity against the immunemodulating activity of the human immunodeficiency vir type1 Tat protein in mice PNAS 99:1003710041 2002.
Arlen PM. et al. Strategies for the Development of PSAbased vaccines for the treatment of advanced prostate cancer Expert Rev. Vaccines vol. 2 No. 4 pp. 483493 2003.
Badley AD. et al. Upregulation of Fas Ligand Expression by Human Immunodeficiency Vir in Human Macrophages Mediates Apoptosis of Uninfected T Lymphocytes J Virol 70:199206 Jan. 1996.
Badley AD. et al. Macrophagedependent Apoptosis of CD4+ T Lymphocytes from HIVinfected Individuals is Mediated by FasL and Tumor Necrosis Factor J. Exp. Med. vol. 185 No. 1 pp. 5564 Jan. 6, 1997.
Baghian, A. et al., “Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunization with herpes simplex virus type-1 genes specifying glycoproteins gB and gD”, Journal of Medical Microbiology, vol. 51, No. 4, 2002, pp. 350-357.
Banchereau J et al. Dendritic cells as vectors for therapy Cell 106:2714 2001.
Bayer P et al. Structural Studies of HIV1 Tat Protein J. Mol. Biol. vol. 247 pp. 529535 1995.
Beissert S. et al. IL10 Inhibits Tumor Antigen Presentation by Epidermal AntigenPresenting Cells The Journal of Immunology vol. 154 pp. 12801286 1995.
Buanec HL et al. A prophylactic and therapeutic AIDS vaccine containing as a component the innocuo Tat Toxoid Biomedicine and Pharmacotheraphy Vo. 52 No. 10 pp. 431435 1998.
Boykins, R.A., et al., “Immunication with a noval HIV-1-Tat multiple-peptide conjugate induces effective immune response in mice”, Peptides, 2000, vol. 21, , pp. 1829-1847.
Cafaro A. et al. Control of SHIV89.6Pinfection of cynomolg monkeys by HIV1 Tat protein vaccine Nature Medicine vol. 5 No. 6 pp. 643650 Jun. 1999.
Caputo A. et al. Immunization with low doses of HIV1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat Vaccine vol. 21 pp. 11031111 2003.
Caselli E. et al. DNA immunization with HIV1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wildtype Tat. J Immunol 162:56318 1999.
Cheadle, C., et al., :“Identification of a Src SH3 Domain Binding Motif by Screening a Random Phage Display Library”, The Journal of Biological Chemistry, 1994, vol. 269, No. 39, pp. 24034-24039.
Chenciner et al. Enhancement of humoral immunity to SIVenv following simultaneo inoculation of mice by three recombinant adenovires encoding SIVenvpoliovir chimeras Tat and Rev. AIDS Res Hum Retrovires 13:8016 1997.
Cho H. et al. In vitro induction of carcioembryonic antigen (CEA)specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenovires Vaccine vol. 22 pp. 224236 2003.
CNN Interactive New HIV Vaccine Concept May Extend Hope to Those Already Infected htt:cnn.comHEALTHaids990829aids.vaccine. pp. Aug. 13, 1999.
Cohen SS et al. Pronounced acute immunosuppression in vivo mediated by HIV1 Tat challenge Proc Natl Acad Sci A 96:1084247 1999.
Dalyotherman N et al. Reversal of CD8+ T cell ignorance and induction of antitumor immunity by peptidepulsed APC J Immunol 165:67317 2000.
Durrant LG et al. Cancer vaccines entering Phase III clinical trials
Bergman Michelle Glasky
Cullman Louis C.
K&L Gates LLP
Mosher Mary E
NaniRx, Inc.
LandOfFree
Tat-based immunomodulatory compositions and methods of their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tat-based immunomodulatory compositions and methods of their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tat-based immunomodulatory compositions and methods of their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2674279